Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.88 |
| ▸ | PGR | P06401 | 6/20 | 0.88 |
| ▸ | AR | P10275 | 5/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.88 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943175 | 1.00 | NR3C1 (0.88) | NR3C1PGRARCYP3A4ADORA3 | |
| SCHEMBL195423 | 0.94 | NR3C1 (0.90) | NR3C1PGRARCYP3A4ADORA3 | |
| SCHEMBL14479087 | 0.94 | NR3C1 (0.90) | NR3C1PGRARCYP3A4ADORA3 | |
| SCHEMBL14421353 | 0.94 | NR3C1 (0.86) | NR3C1PGRARCYP3A4ADORA3 | |
| SCHEMBL13950976 | 0.94 | NR3C1 (0.86) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL9363108 | 0.94 | NR3C1 (0.97) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL9363101 | 0.94 | NR3C1 (0.97) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191133 | 0.94 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4111260 | 0.94 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13993454 | 0.94 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172587-A1 | Process for the Preparation of Fluticasone Propionate | GENERICS [UK] LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| US-20130172587-A1 | Process for the Preparation of Fluticasone Propionate | GENERICS [UK] LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| US-8344168-B2 | Process for the preparation of fluticasone propionate | GENERICS (UK) LIMITED (GB) | 2013-01-01 | — | — | US | disclosed |
| US-8344168-B2 | Process for the preparation of fluticasone propionate | GENERICS (UK) LIMITED (GB) | 2013-01-01 | — | — | US | disclosed |
| US-20090177001-A1 | NOVEL PROCESS AND INTERMEDIATES | GENERICS [UK] LIMITED (INCORPORATED IN THE UNITED KINGDOM] (GB) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172587-A1 | Process for the Preparation of Fluticasone Propionate | CYP17A1, NR5A1, CYP4F3 | NR3C1 41/4885PGR 313/4885AR 108/4885 |
| US-20090177001-A1 | NOVEL PROCESS AND INTERMEDIATES | CYP17A1, NR5A1, CYP21A2 | NR3C1 36/4885PGR 204/4885AR 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.